Genentech’s Top-Line AVADO Data Strong With Avastin For Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Though not registrational, study could bolster NDA package.
You may also be interested in...
Price, Not Safety, Most Likely To Limit Avastin Use In Breast Cancer – JPMorgan Physician Survey
Long-term revenue upside for drug in all indications could be as much as $6.5 billion by 2012, says JPMorgan analyst Geoffrey Meacham.
Price, Not Safety, Most Likely To Limit Avastin Use In Breast Cancer – JPMorgan Physician Survey
Long-term revenue upside for drug in all indications could be as much as $6.5 billion by 2012, says JPMorgan analyst Geoffrey Meacham.
Genentech Watchers Weigh Deeper Meaning Of Avastin’s Approval
FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.